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ABSTRACT 
Nasal drug delivery has been recognized as a promising route for delivery of therapeutic compounds including biopharmaceuticals. It has been 
demonstrated that absorption of drugs can enhance by using absorption enhancers or increasing the drug residence time in the nasal cavity. 
Mucoadhesive polymers can serve both functions. The residence time in the nasal cavity is considerably increased for nanoparticles compared 
to solutions. Topiramate (TPM) is used alone or with other medications to prevent and control seizures (epilepsy). This medication is also used 
to prevent migraine headaches and decrease how often you get them. TPM will not treat a migraine headache once it occurs. The purpose of the 
present study was to prepare and evaluate mucoadhesive chitosan nanoparticles of TPM for the nasal administration by ionic gelation method. 
Nanoparticles were subjected to various characterization techniques such as FTIR, particle size, scanning electron microscopy (SEM), drug 
entrapment efficiency and zeta potential are also determined for the developed formulations. The nanoparticles exhibited mucoadhesive 
properties, which diminished with increasing drug content. The nanoparticles with a particle size range between 45and 62nm exhibited 
excellent mucoadhesive properties. Stability study at various storage temperature was also done in which the prepared formulation showed an 
improved stability. The zeta potential of the best chitosan preparation (F4) was found to be -35.5mV, which confirms the stability of prepared 
nanosuspension. Mucoadhesive chitosan nanoparticles can be a promising carrier for nasal delivery of TPM found to have high encapsulation 
efficiency and predetermined in vitro release profile. 
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INTRODUCTION 
Nasal administration can be used to deliver drugs for either 
local or systemic effect. The nasal route circumvents hepatic 
first pass elimination associated with oral delivery. Rapid 
mucociliary clearance of t drug formulation is responsible 
for the low bioavailability of drugs administered by nasal 
route. To circumvent these problems, mucoadhesive drug 
delivery systems are being developed to provide a long term 
therapeutic concentration of the drug1. The use of 
mucoadhesive polymers for the development of delivery 
system maximizes the residence time of the drug 
formulation in the nasal cavity and hence prolonging the 
period of contact with the nasal mucosa thereby improving 
drug absorption2. Multiparticulate systems like 
nanoparticles, microparticles provide controlled release of 
the drugs. Nanoparticles are colloidal sized particles, 
possessing diameters ranging between 10 and 1000 nm, and 
drugs may be encapsulated, adsorbed or dispersed in them. 
Properties of the nanoparticles are largely dependent on the 
polymers used to prepare it. Chitosan has been shown to 
have mucoadhesive properties because of its viscosity and 
interaction of the positively charged amino group with the 
negatively charged sites on the mucosa surface. Chitosan 
(CS) is a deacetylation derivative of chitin, and is 
biocompatible, biodegradable and non toxic in nature. 
Investigations have suggested that there are two effects of 
chitosan delivery systems on nasal mucosa. The 
mucoadhesive properties of the polymer can reduce the 
clearance rate of drugs from nasal cavity, thereby prolonging 
the contact time of chitosan delivery system with nasal 
epithelium. In addition, it has been shown that the 
interaction of the positively charged amino group of chitosan 
with the negatively charged sialic acid residues in mucus 
causes the transient opening of the tight junctions and 
allows large hydrophilic compounds to be transported 
across the epithelium3. Topiramate (TPM) is a novel 
antiepileptic drug derived from the naturally occurring 
monosaccharide D fructose. It is not structurally related to 
other antiepileptic drugs and was originally synthesized as 
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the part of a search for fructose related compounds with 
hypoglycemic activity4. It has multiple mechanisms of action 
such as sodium and calcium channel blockade; potassium 
channel activation; glutamate receptor antagonism; 
gamma‑aminobutyric acid potentiation and carbonic 
anhydrase inhibition5.  In the present research work, an 
attempt has been made to prepare mucoadhesive 
nanoparticulate system of TPM for nasal delivery by ionic 
gelation method. 
MATERIALS AND METHODS 
Materials 
TPM was procured from MSN Organics Pvt. Ltd., Hyderabad 
as a gift sample. Chitosan was obtained from HiMedia 
Laboratories Ltd, Mumbai, India. STPP, acetic acid, ethanol, 
Span 80, acetone, dichloromethane and light liquid paraffin 
were purchased from Central Drug House Pvt Ltd, Mumbai, 
India. All other reagents and chemicals used were of 
analytical grade. 
Determination of λ max of TPM 
Accurately weighed 10 mg of TPM was dissolved in 10 ml of 
phosphate buffer pH 6.6 in a 10 ml volumetric flask. The 
resulted solution (1000µg/ml) was used to prepare the 
concentration 10μg/ml. The spectrum of this solution was 
recorded in 200-400 nm range using UV spectrophotometer 
(Labindia-3000+). After the complete scan λmax of TPM was 
found 260 nm. 
Preparation of calibration curve 
From stock solutions of TPM 1 ml was taken and diluted up 
to 10 ml. From this solution 0.5, 1.0, 1.5, 2.0 and 2.5 ml 
solutions were transferred to 10ml volumetric flasks and 
maked up the volume to 10 ml with phosphate buffer pH 6.6, 
gives standard drug solution of 5, 10, 15, 20, 25μg/ ml 
concentration. 
Preparation of chitosan nanoparticles of TPM 
Chitosan nanoparticles were prepared by ionotropic gelation 
method6.  
Preparation I: Chitosan solution (0.1, 0.2, 0.3, 0.4, 0.5, 0.6 % 
w/v) was prepared by dissolving chitosan in acetic acid 
(0.1% v/v) at room temperature.  
Preparation II: The drug was dissolved in 5ml of Chitosan 
solution. 
Preparation III: 1% Sodium tripolyphosphate solution was 
prepared. 
Preparation II was added in 50ml of preparation III through 
a disposable syringe needle by gently agitating. The 
dropping rate and falling distance were kept constant. The 
solution was magnetically stirred for half an hour followed 
by filtration and rinsing with distilled water. Nanoparticles 
were obtained which was air dried for twenty four hours 
followed by oven drying for six hours at 40˚C Table 1. 
 
Table 1 Composition of mucoadhesive nanoparticles 
Components Formulation code 
F1 F2 F3 F4 F5 F6 
Topiramate (mg) 10 10 10 10 10 10 
Chitosan (%) 0.1 0.2 0.3 0.4 0.5 0.6 
Acetic acid (%) 0.1 0.1 0.1 0.1 0.1 0.1 
Sodium tripolyphosphate (%) 1.0 1.0 1.0 1.0 1.0 1.0 
Stirring speed (rpm) 600 600 600 600 600 600 
Stirring time (hrs) 2 2 2 2 2 2 
 
Evaluation of nanoparticles           
Measurement of mean particle size 
The mean particle size of the nanoparticles was determined 
by Photo Correlation Spectroscopy (PCS) on a submicron 
particle size analyzer (Malvern particle size analyser) at a 
scattering angle of 90°. A sample (0.5mg) of the 
nanoparticles suspended in 5 ml of distilled water was used 
for the measurement. 
Determination of zeta potential 
The zeta potential of the drug-loaded nanoparticles was 
measured on a zeta sizer (Malvern particle size analyser) by 
determining the electrophoretic mobility in a micro 
electrophoresis flow cell. All the samples were measured in 
water at 25°C in triplicate.   
Drug entrapment efficiency 
The entrapment efficiency of the drug is defined as the ratio 
of the mass of formulations associated drug to the total mass 
of drug. Entrapment efficiency was determined by dialysis 
method. Chitosan nanoparticles entrapped TPM were 
separated from the free drug by dialysis method. The above 
said formulations were filled into dialysis bags and the free 
TPM dialyzed for 24 hours into 50 ml of phosphate buffer pH 
6.6. The absorbance of the dialysate was measured at 260.0 
nm against phosphate buffer pH 6.6 and the absorbance of 
the corresponding blank was measured under the same 
condition. The concentration of free TPM could be obtained 
from the absorbance difference based on calibration curve. 
Calibration curve was made by measuring the absorbance at 
260 nm for known concentrations of TPM solution. 
Drug content 
From the prepared Chitosan nano formulation 1ml of 
suspension is dissolved in the 10 ml of methanol. The 
amount of Topiramate was determined using UV 
spectrophotometer at 260nm.The placebo formulation 
prepared similarly to drug loaded nanoparticles was used as 
blank. The total drug content was calculated.  
In-vitro wash-off test for chitosan nanoparticles 
The mucoadhesive properties of the nanoparticles were 
evaluated using an in-vitro wash-off test. A 1x1 cm piece of 
rat stomach mucosa was tied onto a glass slide (3 inch-by-1 
inch), using thread. Nanoparticles were spread 
(approximately 50) onto the wet rinsed tissue specimen and 
the prepared slide was hung onto one of the groves of a USP 
tablet disintegration test apparatus, with continuous oxygen 
supply. The disintegration test apparatus was operated, 
giving the tissue specimen was given regular up and down 
movements within the beaker of the disintegration 
apparatus, which contained the simulated nasal fluid (pH 
6.6). At the end of 30 min, 1 h and at hourly intervals up to 
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12 h, the number of nanoparticles still adhering onto the 
tissue was counted. 
Shape and Surface Characterization of nanoparticles by 
Scanning Electron Microscopy (SEM) 
From the formulated batches of chitosan nanoparticles 
optimized formulations which showed an appropriate 
balance between the percentage releases were examined for 
surface morphology and shape using scanning electron 
microscope Jeol Japan 6000. Sample was fixed on carbon 
tape and fine gold sputtering was applied in a high vacuum 
evaporator. The acceleration voltage was set at 10 KV during 
scanning. Microphotographs were taken on different 
magnification and higher magnification (200X) was used for 
surface morphology. 
In-vitro diffusion study 
An in-vitro drug release study was performed using modified 
Franz diffusion cell. Dialysis membrane (Hi Media, Molecular 
weight 5000 Daltons) was placed between receptor and 
donor compartments. Nanoparticles equivalent to 10 mg of 
TPM was placed in the donor compartment and the receptor 
compartment was filled with phosphate buffer pH 6.6. The 
diffusion cell was maintained at 37±0.5°C with stirring at 50 
rpm throughout the experiment. At different time interval, 5 
ml of aliquots were withdrawn from receiver compartment 
through side tube and analyzed for drug content by UV 
Visible spectrophotometer at 260 nm7-11. 
Mathematical treatment of in-vitro release data 
 The quantitative analysis of the values obtained in 
dissolution/release tests is easier when mathematical 
formulas that express the dissolution results as a function of 
some of the dosage forms characteristics are used. 
Zero-order kinetics: The pharmaceutical dosage forms 
following this profile release the same amount of drug by 
unit of time and it is the ideal method of drug release in 
order to achieve a pharmacological prolonged action. The 
following relation can, in a simple way, express this model: 
Qt = Qo+ Kot 
where Qtis the amount of drug dissolved in time t, Qo is the 
initialamount of drug in the solution (most times, Qo=0) and 
Kois the zero order release constant. 
First-order kinetics: The following relation expresses this 
model: 
 
where Qtis the amount of drug dissolved in time t, Qois the 
initial amount of drug in the solution and K1is the zero order 
release constant. 
In this way a graphic of the decimal logarithm of the released 
amount of drug versus time will be linear. The 
pharmaceutical dosage forms following this dissolution 
profile, such as those containing water-soluble drugs in 
porous matrices, release drug in a way that is proportional 
to the amount of drug remaining in its interior, in such way, 
that the amount of drug released by unit of time diminish. 
Higuchi model: Higuchi developed several theoretical 
models to study the release of water-soluble and low soluble 
drugs in semi-solid and/or solid matrixes. Mathematical 
expressions were obtained for drug particles dispersed in a 
uniform matrix behaving as the diffusion media. The 
simplified Higuchi model is expressed as: 
 
Where Q is the amount of drug released in time t and KH is 
the Higuchi dissolution constant. Higuchi model describes 
drug release as a diffusion process based in the Fick’s law, 
square root time dependent. This relation can be used to 
describe the drug dissolution from several types of modified 
release pharmaceutical dosage forms such as transdermal 
systems and matrix tablets with water-soluble drugs. 
Korsmeyer-Peppas model: Korsmeyer et al. used a simple 
empirical equation to describe general solute release 
behaviour from controlled release polymer matrices:  
 
Where Mt/Mis fraction of drug released, a is kinetic 
constant, t is release time and n is the diffusional exponent 
for drug release. ’n’ is the slope value of log Mt/M versus log 
time curve. Peppas stated that the above equation could 
adequately describe the release of solutes from slabs, 
spheres, cylinders and discs, regardless of the release 
mechanism. Peppas used this n value in order to 
characterize different release mechanisms, concluding for 
values for a slab, of n =0.5 for fickian diffusion and higher 
values of n, between 0.5 and 1.0, or n =1.0, for mass transfer 
following a non-fickian model. In case of a cylinder n =0.45 
instead of 0.5, and 0.89 instead of 1.0. This equation can only 
be used in systems with a drug diffusion coefficient fairly 
concentration independent. To the determination of the 
exponent n the portion of the release curve where Mt/M< 
0.6should only be used. To use this equation it is also 
necessary that release occurs in a one-dimensional way and 
that the system width-thickness or length-thickness relation 
be at least 10. A modified form of this equation was 
developed to accommodate the lag time (l) in the beginning 
of the drug release from the pharmaceutical dosage form: 
 
When there is the possibility of a burst effect, b, this 
equation becomes: 
 
In the absence of lag time or burst effect, l and bvalue would 
be zero and only atnis used. This mathematical model, also 
known as Power Law, has been used very frequently to 
describe release from several different pharmaceutical 
modified release dosage forms12-14. 
Stability studies for optimized formulation 
Stability of a formulation on storage is of great concern as it 
is the major restraint in their development as marketed 
preparation. Optimized nanoparticle formulation (F4) were 
stored in amber colored bottles and subjected to exhaustive 
stability testing at 4±1°C and room temperature for 3 month 
period. Samples were withdrawn periodically and 
formulation was observed on the basis of % EE, average 
particle size and physical appearance.  
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RESULTS AND DISCUSSIONS 
The λ max of TPM was found to be 260 nm by using U.V. 
spectrophotometer (Labindia-3000+) in linearity range 5-
25µg/ml Figure1, 2. 
 
Figure 1 U.V. Spectra of Pure TPM in phosphate buffer 
pH 6.6 
The particle size is an important parameter as it has a direct 
effect on the stability, cellular uptake, drug release and 
mucodistribution. The mean particle sizes of the prepared 
nanoparticles measured by the Horiba Zetasizer were in size 
range of  45.5±0.9to  62.23±0.7  nm  and  the  distribution  of  
particle  sizes  are  found  to  be monodispersed as the 
polydispersity index lies between 0 to 1 (0.642 to 0.965) in 
all the formulations. There was no noticeable difference 
between the sizes of nanoparticles obtained with different 
drug polymer ratio. The particle morphology can be 
modulated by selecting the agitation speed as well as drug 
polymer ratio. The drug content and % EE of all formulation 
was found to be in range of 63.12±0.5 to78.8±0.2 and 
49.3±0.25 to 63.1±0.56. This is due to the mucoadhesion 
characteristics of chitosan that could facilitate the diffusion 
of part of entrapped drug to surrounding medium during 
preparation of TPM nanoparticles. The maximum drug 
content and entrapment efficiency was found formulation F4 
Table 2 & Figure 3. 
 
Figure 2 Calibration Curve of TPM in phosphate buffer 
pH 6.6  
 
 
  Table 2 Evaluation of nanoparticle formulations  
Formulation Particle  Size* (nm) Entrapment efficiency* (%) Drug content* (%) Poly-dispersity index* 
F1 55.65±0.4 58.2±0.45 69.98±0.5 0.965±0.023 
F2 62.23±0.7 55.6±0.32 65.45±0.1 0.912±0.041 
F3 52.23±0.5 51.9±0.41 63.12±0.5 0.885±0.036 
F4 45.5±0.9 63.1±0.56 78.8±0.2 0.642±0.049 
F5 58.89±0.4 49.3±0.25 69.98±0.4 0.756±0.036 
F6 62.23±0.3 54.32±0.25 70.12±0.2 0.841±0.041 
*Average of three determinations (n=3) 
 
Figure 3 Graph of evaluation of nanoparticle 
formulations 
The results of in vitro mucoadhesion carried out showed that 
all the prepared formulation had good mucoadhesive 
property. It was found that increase in the concentration of 
chitosan in the formulation increased the mucoadhesion 
from 56.65±0.23 to 72.12±0.56% (F1 to F6). Formulation F4 
showed maximum mucoadhesion 72.12±0.56 % Table 3 & 
Figure 4. 
The results of measurement of mean particle size of 
optimized formulation F4 nanoparticles were found 
45.5±0.9nm and zeta potential of optimized formulation F4 
nanoparticles was found to be -35.5 mV Figure 5. 
Table 3 Evaluations of percent mucoadhesion 
S. 
No. 
Formulation 
Code 
Percent 
Mucoadhesion 
1 F1 56.65±0.23 
2 F2 62.23±0.41 
3 F3 63.23±0.32 
4 F4 72.12±0.56 
5 F5 69.98±0.76 
6 F6 59.45±0.34 
*Average of three determinations (n=3) 
 
Figure 4 Graph of evaluations of percent mucoadhesion 
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Figure 5 Zeta potential of optimized formulation (F4) 
The in vitro release profiles of the optimized formulation F4 
were carried out in pH 6.6 Phosphate buffer for 6 h. 
Sustained release of the drug from the NPs is important as it 
would allow for a prolonged residence of the drug at the 
absorption site, increasing drug bioavailability. The in vitro 
drug release data of the optimized formulation was 
subjected to goodness of fit test by linear regression analysis 
according to zero order, first order kinetic equation, 
higuchi’s and korsmeyer’s models in order to determine the 
mechanism of drug release. When the regression coefficient 
values were compared, it was observed that ‘r2’ values of 
first order were maximum i.e. 0.946 hence indicating drug 
releases from formulation follow first order release kinetics. 
Table 4, 5 & Fig. 7, 8.  
 
Table 4 In-vitro drug release data for F4 
Time 
(h) 
Square Root 
of Time(h)1/2 
Log Time 
Cumulative*% Drug 
Release 
Log Cumulative 
% Drug Release 
Cumulative %  
Drug Remaining 
Log Cumulative 
% Drug 
Remaining 
0.5 0.707 -0.301 8.23±0.53 0.9154 91.77 1.963 
1 1.000 0.000 16.69±0.42 1.2225 83.31 1.921 
1.5 1.225 0.176 22.32±0.64 1.3487 77.68 1.890 
2 1.414 0.301 44.56±0.13 1.6489 55.44 1.744 
2.5 1.581 0.398 56.69±0.27 1.7535 43.31 1.637 
3 1.732 0.477 69.98±0.14 1.8450 30.02 1.477 
4 2.000 0.602 73.32±0.65 1.8652 26.68 1.426 
6 2.449 0.778 83.32±0.89 1.9207 16.68 1.222 
*Average of three determinations (n=3) 
 
 
Figure 7 Zero order release kinetics 
 
 
Figure 8 First order release kinetics  
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Table 5 Regression analysis data of mucoadhesive 
nanoparticles 
Batch 
Zero Order First Order 
r² r² 
F4 0.848 0.946 
 
CONCLUSION 
Chitosan NPs exhibit significant mucoadhesive properties 
and could potentially be used for sustained intranasal 
delivery of antiepileptic drugs. We successfully formulated 
in the form of a chitosan nanoparticle system and the 
formulation was optimized by considering the concentration 
of chitosan, chitosan/TPP ratio and nanoparticle size 
distribution. In vitro release studies showed that the drug is 
released from the optimized formulation over a period of 6 
hr in a sustained release manner. This produces a 
formulation which is a viable alternative to conventional 
methods by virtue of its ability to sustain the drug release 
and for its ease of administration because of reduced dosing 
frequency, resulting in better patient compliance. 
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